Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) Antibody

Este producto es parte de AKR1B - Aldo-keto reductase family 1 member B
Product Graph
260€ (50 µl)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx211069
tested applications
ELISA, WB, IHC

Description

AKR1B10 Antibody is a Rabbit Polyclonal against AKR1B10.

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

CategoryPrimary Antibodies
Immunogen TargetAldo-Keto Reductase Family 1 Member B10 (AKR1B10)
HostRabbit
ReactivityHuman
Recommended DilutionELISA: 1/2000 - 1/5000, WB: 1/200 - 1/1000, IHC: 1/25 - 1/100. Optimal dilutions/concentrations should be determined by the end user.
ClonalityPolyclonal
ConjugationUnconjugated
IsotypeIgG
PurificationAntigen Affinity Chromatography.
Size 150 µl
Size 2100 µl
FormLiquid
Tested ApplicationsELISA, WB, IHC
BufferPBS, pH 7.4, containing 0.05% NaN3 and 40% Glycerol.
AvailabilityShipped within 5-10 working days.
StorageAliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Dry IceNo
UniProt IDO60218
Gene ID57016
AliasAKR1B10,AKR1B11,AKR1B12,ALDRLn,ARL-1,ARL1
BackgroundAntibody anti-AKR1B10
StatusRUO

Descripción

AKR1B10 is primarily expressed in the liver, intestines, and lungs, where it catalyzes the reduction of carbonyl compounds, including aldehydes derived from lipid peroxidation and retinoic acid metabolism. AKR1B10 plays a pivotal role in detoxifying reactive aldehydes, thereby protecting cells from oxidative stress and lipid damage. It also regulates cellular retinoic acid levels, influencing cell proliferation, differentiation, and apoptosis. Overexpression of AKR1B10 is strongly associated with various cancers, particularly hepatocellular carcinoma (HCC), non-small-cell lung cancer (NSCLC), and colorectal cancer, where it enhances tumor progression, chemoresistance, and metastasis. AKR1B10 contributes to drug resistance by metabolizing chemotherapeutic agents and supporting lipid synthesis for tumor growth. Its role in fatty acid biosynthesis links it to metabolic reprogramming in cancer cells, promoting proliferation and survival. AKR1B10 is considered a promising biomarker for cancer diagnosis and prognosis, as well as a therapeutic target for improving cancer treatment outcomes.

Related Products

EH1225

Human AKR1B10(Aldo-keto reductase family 1 member B10) ELISA Kit

Ver Producto
P2205

Recombinant Human akr1b10

Ver Producto
P4199

Recombinant Human AKR1B10

Ver Producto